Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

247
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
247
T Cell Types and Functions01:24

T Cell Types and Functions

1.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.3K
Inflammatory Response01:28

Inflammatory Response

5.3K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
5.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

257
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
257
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

426
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
426

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Insights into Skeletal Muscle Metabolism in Pathological and Physiological Conditions: A Multidisciplinary and Translational Approach.

Biology·2026
Same author

Eating behaviours, prevalence of obesity & health policies.

International journal of food sciences and nutrition·2026
Same author

Italy's Landmark Obesity Law: The Long Road from Science to Policy.

Obesity facts·2026
Same author

Exercise-derived extracellular vesicles in oncology: a new frontier for translational nanomedicine.

Journal of translational medicine·2026
Same author

Synaptic Plasticity in Neurodegenerative Diseases: Impact of Exercise as Promising Therapeutic Tool.

Cells·2026
Same author

Self-Templated Highly Porous Gold Electrodes for Antibiofouling Electrochemical (Bio)Sensors.

Nanomaterials (Basel, Switzerland)·2026

Related Experiment Video

Updated: Aug 29, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.1K

The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.

Tania Colasanti1, Katia Stefanantoni1, Cristina Fantini2

  • 1Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155-00161 Rome, Italy.

International Journal of Molecular Sciences
|September 9, 2022
PubMed
Summary

Iloprost treatment reduced the chemokine CXCL10 in systemic sclerosis (SSc) patients and in cell models. This suggests iloprost may help manage SSc by targeting CXCL10, a marker of disease progression.

Keywords:
CXCL10human endothelial cellshuman fibroblastsiloprostsystemic scleroderma

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

531
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

7.5K

Related Experiment Videos

Last Updated: Aug 29, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.1K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

531
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

7.5K

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis and vascular damage.
  • Current treatments for SSc lack efficacy, and reliable biomarkers for disease onset and progression are needed.
  • The chemokine interferon gamma-induced protein 10 (IP-10/CXCL10) is associated with SSc progression and poor prognosis.

Purpose of the Study:

  • To investigate the effect of iloprost on CXCL10 expression and signaling in endothelial cells and dermal fibroblasts.
  • To evaluate serum CXCL10 levels in SSc patients treated with iloprost compared to untreated patients.

Main Methods:

  • Human endothelial cells and dermal fibroblasts were stimulated with IFNγ/TNFα, with or without iloprost, to assess CXCL10 secretion and intracellular signaling pathways (STAT1, NF-kB, JNK, PI3K/AKT, ERK1/2).
  • Serum CXCL10 levels were quantified in SSc patients receiving iloprost and in a control group of untreated SSc patients.

Main Results:

  • Iloprost significantly reduced CXCL10 secretion and expression in vitro, largely preventing IFNγ/TNFα-dependent signaling in endothelial cells.
  • Serum CXCL10 levels were significantly lower in SSc patients treated with iloprost compared to untreated SSc patients.

Conclusions:

  • Iloprost demonstrates a potential to inhibit CXCL10 at both local (vascular/dermal) and systemic levels in SSc.
  • These findings support further research into iloprost's role in improving the understanding and management of SSc.